Journal of Blood Disorders & Transfusion

Associated inosine triphosphate pyrophosphatase gene polymorphisms and interferon/ribavirin-induced anemia in Egyptian HCV patients

7^th World Hematologists Congress

May 08-09, 2017 Barcelona, Spain

Olfat M Hendy, Rawhia H El-Adel, Enas Said Essa, Maha M El-Sabawy and Heba Mohamed Abdullah

Menoufia University, Egypt

Posters & Accepted Abstracts: J Blood Disord Transfus

Abstract:

Background: It has been found that ITPase deficiency is caused by ITPA gene polymorphisms. It was observed that ITPA polymorphisms have impact on hematological changes, including hemoglobin (Hb)-decline and platelet decline during treatment of chronic hepatitis C (CHC) patients with pegylated-interferon (PEG-IFN) plus ribavirin (RBV). Aim: Aim of this study is to evaluate the association of inosine triphosphate pyrophosphatase (ITPA) gene polymorphism rs1127354 and rs7270101 with the development of anemia in chronic hepatitis C (CHC) Egyptian patients during treatment with pegylatedinterferon (PEG-IFN) plus ribavirin (RBV). Methods: The current study included 100 selected Egyptian CHC patients treated with PEG-IFN/RBV, 55 patients developed anemia (Hb decline>2 g\dl) and other 45 would not develop anemia (Hb decline�?�2 g\dl) at week 12 throughout the treatment course. Routine laboratory investigations were done for all participants (HCV-Abs, HBs Ag, HCV-RNA levels, complete blood picture, Liver and kidney function tests, AFP and TSH).Single nucleotide polymorphism (SNP) was done using real time PCR, ABI TaqMan allelic discrimination kit for ITPA polymorphisms (rs1127354 and rs7270101). Results: CC and AA were the most prevalent genotypes of SNPs rs1127354 and rs7270101 respectively among two studied groups. In univariate analysis, we found that rs1127354 polymorphism was associated with Hb-decline at week 12 of treatment; this demonstrated the protective benefit of the minor allele A of rs1127354 against RBV-induced anemia at the week 12 of therapy. Ge¬notyping of ITPA rs1127354 and rs7270101 polymorphism would be ben¬eficial for predicting platelet decline during treatment. Patients with CC rs1127354 and AA rs7270101 were found to have a lower level of platelet decline. Conclusion: It is concluded that minor allele A of rs1127354 plays a crucial role in protection against RBV-induced anemia. Genotyping of ITPA rs1127354 and rs7270101 polymorphism would be beneficial for predicting platelet decline during treatment with PEG-IFN plus RBV in Egyptian patients with chronic hepatitis C.

Biography :

Email: olfat_hendy@hotmail.com